Stock Ratings / Health Care / QDEL / financials

ACHV (44) MYGN (39) NNNN (45) TKNO (44) ⌘ Pro Terminal →

QuidelOrtho Corporation (QDEL) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$13.76 -1.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

QuidelOrtho Corporation (QDEL) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $943.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QDEL)Realized 20D OHLCV Swing Band: ±12.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How QDEL Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $3.00B

FY24

Rev $2.78B

FY25

Rev $2.73B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$2.73B	52%	-33.7%	-$1.13B	-$83.0M	-41.5%
FY 2024	$2.78B	52%	-70.5%	-$2.05B	-$112.1M	-45%
FY 2023	$3.00B	52%	4.6%	-$10.1M	$280.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QDEL)

✓Walkthrough of QDEL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

QDEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.87%⚡ TESTING RESISTANCE

2026-10-30O $13.45H $13.76L $12.48C $13.76VOL 1.74M

RES: $14.49SUP: $9.11SMA50: $12.76SMA200: $16.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QDEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QDEL Butterfly Map → + Track QDEL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -1.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on QDEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QDEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for QDEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QDEL)

Health Care Rank #940 of 1016 ⚔️ ACHV vs QDEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QDEL vs. ACHV, MYGN, NNNN, TKNO)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, QuidelOrtho Corporation (QDEL) ranks #940 by composite RQD confidence (30/100, grade E) and #367 by equity capitalization ($943.6M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with QDEL at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
QDEL ACTIVE QuidelOrtho Corporation	E	30/100	—	—	-35.0%	-1.78%	$943.6M	Benchmark Subject
ACHV Achieve Life Sciences Inc.	D	44/100	—	—	-35.0%	+4.96%	$739.9M	/achv-vs-qdel →
MYGN Myriad Genetics Inc.	D-	39/100	—	69.9%	-35.0%	+0.60%	$638.0M	/mygn-vs-qdel →
NNNN Anbio Biotechnology (Class A)	D	45/100	83.6x	87.2%	17.0%	-3.12%	$535.3M	/nnnn-vs-qdel →
TKNO Alpha Teknova Inc.	D	44/100	—	33.2%	-21.3%	+2.93%	$499.2M	/tkno-vs-qdel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-28 • CIK 0001906324

In its most recent audited fiscal period (FY2025, filed 2025-12-28), QuidelOrtho Corporation (QDEL) reported GAAP revenue of $2.73B (-1.9% vs. FY2024 revenue of $2.78B , and -8.9% cumulative change since FY2023) , GAAP net income of -$1.13B, operating cash flow of $105.2M, and free cash flow of -$83.0M (+26.0% YoY). On the balance sheet, QDEL closed FY2025 with $5.77B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-28	$2.73B	-$1.13B	$105.2M	-$83.0M	$5.77B	—
FY2024 (FY)	2024-12-29	$2.78B	-$2.05B	$83.0M	-$112.1M	$6.42B	—
FY2023 (FY)	2023-12-31	$3.00B	-$10.1M	$280.2M	$280.2M	—	—

3. QDEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QDEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, QuidelOrtho Corporation (NASDAQ: QDEL) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $13.76 (-1.78% 1D, market cap $943.6M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, QDEL ranks #940 in composite RQD confidence.

How does QDEL compare to ACHV and MYGN in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), QDEL carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACHV (Achieve Life Sciences Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $739.9M) and MYGN (Myriad Genetics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $638.0M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QDEL?

Per QDEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0001906324), QuidelOrtho Corporation generated $2.73B in revenue (-1.9% YoY), -$1.13B in net income, and -$83.0M in free cash flow against $5.77B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QDEL trading relative to its 50-day, 200-day, and 52-week technical levels?

QDEL last traded at $13.76 (-1.78% on volume of 1,509,036 shares), positioning the stock +7.84% above its 50-day simple moving average ($12.76) and -15.38% below its 200-day simple moving average ($16.26). Across its 52-week range of $9.92 to $35.58, QDEL sits at the 15.0% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($12.04 to $15.48).